Purpose: To evaluate the effectiveness and safety of gefitinib retreatment beyond disease progression in patients with advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor () mutations.
Methods: Data from patients with stage III/IV NSCLC were analyzed retrospectively. Patients with sensitive mutations received first-line treatment with gefitinib followed by retreatment with gefitinib after disease progression. Progression-free survival (PFS) after the first treatment (PFS-1) was defined as the time to progression or death using the Response Evaluation Criteria in Solid Tumors criteria (RECIST) v1.1 criteria. The second PFS (PFS-2) was defined as the interval between the first and second progressions, at the investigator's discretion. Toxicities were recorded in accordance with the National Cancer Institute (NCI)-Common Terminology Criteria (CTC) version 4.0.
Results: Sixteen patients aged 53 to 80 years (median 66 years) were included in the analysis. The median PFS-1 and PFS-2 were 10.0 months and 14.0 months, respectively. The median overall survival (OS) was 36.0 months. No toxicity of grade 3 or worse was observed.
Conclusions: Our findings suggest that gefitinib retreatment beyond disease progression may be an effective and tolerable approach for NSCLC patients with sensitive mutations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550958 | PMC |
| http://dx.doi.org/10.1177/0300060520955030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive mutations.
J Int Med Res
October 2020
Department of Oncology, the People's Hospital of Bishan District, Bishan, Chongqing, China.
Purpose: To evaluate the effectiveness and safety of gefitinib retreatment beyond disease progression in patients with advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor () mutations.
Methods: Data from patients with stage III/IV NSCLC were analyzed retrospectively. Patients with sensitive mutations received first-line treatment with gefitinib followed by retreatment with gefitinib after disease progression.
Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants.
J Thorac Dis
August 2020
Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Article Synopsis
- - The study aimed to estimate how common and what factors contribute to fatal toxic effects from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell lung cancer (NSCLC).
- - Researchers reviewed 53 clinical trials with nearly 10,000 participants, finding that 1.33% experienced fatal toxic effects, particularly noting higher incidences in Japanese patients and those undergoing first-line treatments.
- - The most frequent cause of these fatalities was interstitial lung disease (ILD), followed by pneumonia, respiratory failure, and diarrhea, highlighting the need for better risk assessment in specific patient populations.
Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Am Soc Clin Oncol Educ Book
January 2019
4 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Personalized therapy based on actionable molecular markers has completely transformed the therapeutic landscape in advanced non-small cell lung cancer (NSCLC). In less than 15 years, multiple molecular targets, led by EGFR and anaplastic lymphoma kinase (ALK), have been identified, and myriad oral tyrosine kinase inhibitors (TKIs) are now available to target these oncogenic drivers, with the expectation that the majority of patients will respond to treatment and that progression-free survival (PFS) will exceed 10 to 30 months, far better than we observed historically with chemotherapy alone. As a result, prognosis has improved dramatically in this subset of patients.
View Article and Find Full Text PDFBackground: Locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after first-line treatment has a poor prognosis. Recent randomized clinical trials (RCTs) have demonstrated survival benefits of alternative treatments to docetaxel. However, information is lacking on which patients benefit the most and what drug or regimen is optimal.
View Article and Find Full Text PDFPneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Lung Cancer
September 2018
Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston MA, USA. Electronic address:
Purpose: Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in clinical trials of EGFR-TKI published in 2003-2017, and performed subgroups analyses to identity predisposing factors.
Methods: Ovid-MEDLINE and EMBASE search up to 4/17/17 using the keywords, "erlotinib", "gefitinib", "afatinib", "osimertinib", and "lung cancer", resulted in a total of 153 eligible trial cohorts with 15,713 advanced NSCLC patients treated with EGFR-TKI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!